BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) announced today the appointment of Bo Joelsson, M.D., Ph.D., as head of clinical research reporting to Alan Harris, M.D., Ph.D., senior vice president R & D and chief medical officer of NPS. One of Dr. Joelsson’s key responsibilities at NPS will be to advance the clinical development of GATTEX™ (teduglutide), the company’s investigational drug for the treatment of intestinal failure associated with short bowel syndrome, necrotizing enterocolitis and gastrointestinal mucositis. Dr. Joelsson, a specialist in gastroenterology, brings 15 years of clinical experience and 20 years of global pharmaceutical industry experience to NPS. He has led the clinical development of several major gastrointestinal products, including Tagamet® (cimetidine), Prilosec® (omeprazole), and Nexium® (esomeprazole magnesium).
